Eyefinity vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Optometry and optical PMS owned by VSP Global, serving independent eyecare practices across the US. Rancho Cordova CA; OfficeMate covers scheduling, billing, and EHR; iMedicWare handles optical point-of-sale and lab orders;
About
Eyefinity is a Rancho Cordova, California-based optometry and optical practice management software company owned by VSP Global, the largest vision care benefits plan in the United States. Eyefinity provides practice management, electronic health records, and optical lab connectivity tools specifically designed for independent optometrists and optician-led optical retail businesses. The company's products include OfficeMate for practice scheduling, billing, and medical records; ExamWRITER for clinical charting and electronic prescriptions; and iMedicWare for optical point-of-sale and lab order management. Eyefinity's products are used by tens of thousands of eye care professionals across the U.S., many of whom are part of the VSP network of independent optometrists.\n\nEyefinity's connection to VSP Global gives it several advantages in the independent optometry market. VSP's vision care network includes a large proportion of independent optometrists who are naturally inclined toward Eyefinity software because of the seamless VSP insurance eligibility verification and claim submission integration that simplifies the billing workflow for VSP patients—which constitute a significant portion of most private-practice optometry patient volumes. This network integration effectively makes Eyefinity the path of least resistance for VSP-affiliated optometrists seeking practice management software, creating a built-in distribution advantage.\n\nEyefinity has been modernizing its product portfolio through cloud-based offerings and improved user interfaces as competitive pressure from newer optometry software entrants increases. The company competes with Compulink Healthcare Solutions, Revolution EHR, and Crystal Practice Management in the optometry practice management market. Eyefinity differentiates on its VSP integration depth, its large installed base in the VSP network, and the operational trust that comes from being backed by the dominant vision care benefits plan in the United States.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.